evrazkarЕвразийский Кардиологический ЖурналEurasian heart journal2225-16852305-0748Евразийская ассоциация кардиологов10.38109/2225-1685-2019-3-50-64evrazkar-337Research ArticleОБЗОРREVIEWСЕРДЕЧНО-СОСУДИСТЫЕ ОСЛОЖНЕНИЯ ПОСЛЕ ПРОТИВООПУХОЛЕВОЙ ТЕРАПИИ У ОНКОЛОГИЧЕСКИХ БОЛЬНЫХ В ОТДАЛЕННЫЕ СРОКИ (>1 ГОДА)LONG-TERM CARDIOVASCULAR COMPLICATIONS IN ONCOLOGIC PATIENTS AFTER ANTITUMOR THERAPY (>1 YEAR)КазанцеваМ. Л.KazantsevaM. L.

аспирант отдела гипертонии

121552, Россия, Москва, ул. 3-я Черепковская, д.15А.

Post-Graduate, Hypertension Department

15a 3rd Cherepkovskaya St., Moscow, 121552, Russia

mariakaz777@gmail.comОщепковаЕ. В.OshchepkovaE. V.

д.м.н., профессор, главный научный сотрудник отдела гипертонии

121552, Россия, Москва, ул. 3-я Черепковская, д. 15 а

MD, Professor, Chief Researcher at the Hypertension Department

15a 3rd Cherepkovskaya St., Moscow, 121552, Russia

noemail@neicon.ruСаидоваМ. А.SaidovaM. A.

д.м.н., профессор, руководитель отдела ультразвуковых методов исследования 

121552, Россия, Москва, ул. 3-я Черепковская, д. 15 а.

MD, Professor, Head of the Department for Ultrasonic Research Methods

15a 3rd Cherepkovskaya St., Moscow, 121552, Russia

noemail@neicon.ruАвалянА. А.AvalyanA. A.

аспирант отдела ультразвуковых методов исследования

121552, Россия, Москва, ул. 3-я Черепковская, д. 15 а.

Post-Graduate, Department for Ultrasonic Research Methods

15a 3rd Cherepkovskaya St., Moscow, 121552, Russia

noemail@neicon.ruЧазоваИ. Е.ChazovaI. F.

академик РАН, профессор, д.м.н., директор, руководитель отдела гипертонии 

121552,Россия, Москва, ул. 3-я Черепковская, д. 15 а.

Academician of the Russian Academy of Sciences, Professor, MD, Director, Head of the Hypertension Department

15a 3rd Cherepkovskaya St., Moscow, 121552, Russia

noemail@neicon.ruИнститут клинической кардиологии им. А.Л. Мясникова ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава РоссииРоссияA.L. Myasnikov Clinical Cardiology Institute Federal State Budgetary Institution «National Medical Research Center of Cardiology,» Russian Ministry of HealthcareRussian Federation201930092019035064Copyright © Казанцева М.Л., Ощепкова Е.В., Саидова М.А., Авалян А.А., Чазова И.Е., 20192019Казанцева М.Л., Ощепкова Е.В., Саидова М.А., Авалян А.А., Чазова И.Е.Kazantseva M.L., Oshchepkova E.V., Saidova M.A., Avalyan A.A., Chazova I.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.heartj.asia/jour/article/view/337

Онкологические и сердечно-сосудистые заболевания (ССЗ) занимают лидирующие позиции среди причин смертности населения во многих странах мира, включая Российскую Федерацию [1]. За последние годы в мире отмечается снижение смертности от онкологических заболеваний (ОЗ) благодаря ранней диагностике, разработке и внедрению новых технологий и терапевтических стратегий лечения (химиотерапия, таргетная и лучевая терапии). Среди больных с ОЗ, получивших химио- и лучевую терапии, одной из ведущих причин неблагоприятного прогноза, включая смерть, являются ССЗ [2-5]. Отдаленные последствия кардиотоксических эффектов противоопухолевой терапии (химио-, лучевая терапия) снижают выживаемость и качество жизни больных, перенесших онкологические заболевания. Таким образом, ранняя диагностика и своевременное выявление кардиотоксического эффекта, после проведенного противоопухолевого лечения является одной из основных задач кардиоонкологии.

Oncological and cardiovascular diseases (CVD) hold a leading position among the causes of mortality in many countries of the world, including the Russian Federation [1]. In recent years, a decrease in mortality due to oncologic diseases (OD) is noted around the world thanks to early diagnostics, as well as to the development and implementation of new technologies and therapeutic treatment strategies (chemotherapy, targeted and radiation therapy). Among patients with OD who received chemotherapy and radiation therapy, CVD is one of the leading causes of poor prognosis, including lethal outcomes [2-5]. The long-term cardiotoxic effects of antitumor therapy (chemotherapy, radiation therapy) reduce the survival rate and quality of life of patients who suffer from cancer. Thus, early diagnostics and timely detection of the cardiotoxic effects that follow antitumor treatment is one of the main tasks of cardio-oncology.

кардиоонкологиякардиотоксичностьартериальная гипертониясердечная недостаточностьонкологиятехнология спекл трекинглучевая терапияхимиотерапияcardio-oncologycardiotoxicityarterial hypertensionheart failureoncologyspeckle tracking technologyradiation therapychemotherapyReferencesJose Luis Zamorano, Patrizio Lancellotti, Daniel Rodriguez Munoz, Victor Aboyans, Riccardo Asteggiano et al. 2016 ESC Position Paper on cancer treatment and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Heart Journal. 2016,August 26. doi: 10.1093/eurheartj/ehw211.Jose Luis Zamorano, Patrizio Lancellotti, Daniel Rodriguez Munoz, Victor Aboyans, Riccardo Asteggiano et al. 2016 ESC Position Paper on cancer treatment and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Heart Journal. 2016, August 26. doi: 10.1093/eurheartj/ehw211.Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970–2002. JAMA. 2005; 294:1255-1259. doi: 10.1001/jama.294.10.1255Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970–2002. JAMA. 2005; 294:1255-1259. doi:10.1001/jama.294.10.1255Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220-241. doi: 10.3322/caac.21149Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62:220-241. doi: 10.3322/caac.21149Jemal A, Ward E, Thun M. Declining death rates reflect progress against cancer [serial online]. PLoS One. 2010;5:e9584. doi: 10.1371/journal.pone.0009584.Jemal A, Ward E, Thun M. Declining death rates reflect progress against cancer [serial online]. PLoS One. 2010; 5:e9584. doi: 10.1371/journal.pone.0009584.Bodai BI, Tuso P. Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J. 2015;19:48-79. doi: 10.7812/TPP/14-241Bodai BI, Tuso P. Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J. 2015; 19:48-79. doi: 10.7812/TPP/14-241Howlader N, Ries LAG, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst. 2010;102:1584-1598. doi: 10.1093/jnci/djq366.Howlader N, Ries LAG, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst. 2010; 102:1584-1598. doi: 10.1093/jnci/djq366.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65: 5-29. doi: 10.3322/caac.21254.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65: 5-29. doi: 10.3322/caac.21254.Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov. 2011;10:111126. doi: 10.1038/nrd3252.Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov. 2011; 10:111126. doi: 10.1038/nrd3252.Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 10: 4–12. / Chazova I.Ye., Zhernakova Yu.V., Oshchepkova E.V. The prevalence of risk factors for cardiovascular diseases in the Russian population of patients with arterial hypertension. Cardiology. 2014; 10: 4-12 [in Russian].Chazova I.E., Zhernakova Yu.V., Oshchepkova E.V. The prevalence of risk factors for cardiovascular diseases in the Russian population of patients with arterial hypertension. Cardiology. 2014; 10: 4-12 [in Russian].Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004;291(20):2441-7. doi: 10.1001/jama.291.20.2441Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291(20):2441-7. doi:10.1001/jama.291.20.2441Hequet O, Le Q. H., Moullet I. et al., “Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults,” Journal of Clinical Oncology, vol. 22, no. 10, pp. 1864–1871, 2004. DOI: 10.1016/j.jacc.2017.09.1096Hequet O, Le Q. H., Moullet I. et al., “Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults,” Journal of Clinical Oncology, vol. 22, no. 10, pp. 1864–1871, 2004. DOI: 10.1016/j.jacc.2017.09.1096Szmit S, Jurczak W., Zaucha J. M. et al., “Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma,” Journal of the American Society of Hypertension, vol. 8, no. 11, pp. 791–799, 2014. DOI: 10.1016/j.jash.2014.08.009Szmit S, Jurczak W., Zaucha J. M. et al., “Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma,” Journal of the American Society of Hypertension, vol. 8, no. 11, pp. 791–799, 2014. DOI: 10.1016/j.jash.2014.08.009Robin K. Kuriakose, Rakesh C. Kukreja, Lei Xi. Potential Therapeutic strategies for hypertension-exacerbated cardiotoxicity of anticancer drugs. Oxidative Medicine and Cellular Longevity, 2016. DOI:10.1155/2016/8139861Robin K. Kuriakose, Rakesh C. Kukreja, Lei Xi. Potential Therapeutic strategies for hypertension-exacerbated cardiotoxicity of anticancer drugs. Oxidative Medicine and Cellular Longevity, 2016. DOI:10.1155/2016/8139861Чазова И.Е., Тюляндин С.А., Виценя М.В. и др. Руководство по диагностике, профилактике и лечению сердечнососудистых осложнений противоопухолевой терапии. Часть I. Системные гипертензии. 2017; 14 (3): 6–20. DOI: 10.26442/2075-082X_14.3.6-20/ Chazova I.Ye., Tyulyandin S.A., Vitsenia M.V. et al. Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I. Systemic Hypertension. 2017; 14 (3): 6–20. DOI: 10.26442/2075-082X_14.3.6-20 [in Russian].Chazova I.E., Tyulyandin S.A., Vitsenia M.V., et al. Clinical Manual for the Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I. Systemic Hypertension. 2017; 14 (3): 6–20. DOI: 10.26442/2075-082X_14.3.6-20 [in Russian].Авалян А.А., Кириллова М.Ю., Шитов В.Н. и др. Поиск ранних маркеров кардиотоксичности противоопухолевого лечения у больных раком молочной железы в зависимости от уровня артериального давления. Системные гипертензии. 2017; 14 (3): 21–27. DOI: 10.26442/2075-082X_14.3.21-27/ Avalyan A.A., Kirillova M.Yu., Shitov V.N. et al. Markers of early cardiotoxicity in patients with breast cancer undergoing chemotherapy depending on blood pressure level. Systemic Hypertension. 2017; 14 (3): 21–27. DOI: 10.26442/2075-082X_14.3.21-27. [in Russian].Avalyan A.A., Kirillova M.Yu., Shitov V.N., et al. Search for early markers of cardiotoxicity in patients with breast cancer undergoing chemotherapy depending on blood-pressure level. Systemic Hypertension. 2017; 14 (3): 21–27. DOI: 10.26442/2075-082X_14.3.21-27. [in Russian].Авалян А.А, Саидова М.А., Ощепкова Е.В, Чазова И.Е., Современные подходы к кардиотоксичности индуцированной химиотерапией, у больных раком молочной железы. Евразийский кардиологический журнал, 2018, Сентябрь 20. 3:50-55/ Avalyan A.A., Saidova M.A., Oshepkova E.V., Chazova I. Ye. Modern approaches to detecting early subclinical cardiotoxicity induced by chemotherapy in patients with breast cancer. Eurasian cardiological journal. 2018, September 20; 3: 56-61[in Russian].Avalyan A.A., Saidova M.A., Oshchepkova E.V., Chazova I.E. Modern approaches to detecting early subclinical cardiotoxicity induced by chemotherapy in patients with breast cancer. Eurasian Cardiological Journal. 2018, September 20; 3: 56-61 [in Russian].Авалян А.А., Ощепкова Е.В., Саидова М.А. и др. Оценка субклинической кардиотоксичности антрациклинсодержащей имиотерапии рака молочной железы в зависимости от кумулятивной дозы доксорубицина и исходного уровня артериального давления. Системные гипертензии. 2018; 15 (4): DOI: 10.26442/2075082X.2018.4.000021/ Avalyan A.A., Oshchepkova E.V., Saidova M.A. et al. Evaluation of subclinical cardiotoxicity in patients with breast cancer and arterial hypertension in two regimens of anthracycline- containing chemotherapy. Systemic Hypertension. 2018; 15 (4): DOI: 10.26442/2075082X.2018.4.000021 [in Russian].Avalyan A.A., Oshchepkova E.V., Saidova M.A., et al. Evaluation of subclinical cardiotoxicity in patients with breast cancer and arterial hypertension in two regimens of anthracyclinecontaining chemotherapy. Systemic Hypertension. 2018; 15 (4): DOI: 10.26442/2075082X.2018.4.000021 [in Russian].Lipshultz S. E., Landy D. C., Lopez-Mitnik G., et al. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. Journal of Clinical Oncology. 2012;30(10):1050–1057. DOI: 10.1200/JCO.2010.33.7907.Lipshultz S.E., Landy D.C., Lopez-Mitnik G., et al. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. Journal of Clinical Oncology. 2012;30(10):1050–1057. DOI: 10.1200/JCO.2010.33.7907.Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109:3122-3131. doi: 10.1161/01.CIR.0000133187.74800.B9Yeh E.T., Tong A.T., Lenihan D.J., et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004; 109:3122-3131. doi: 10.1161/01.CIR.0000133187.74800.B9Armstrong GT, Kawashima T, Leisenring W, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the Childhood Cancer Survivor Study. J Clin Oncol. 2014;32:1218-1227. doi: 10.1200/JCO.2013.51.1055.Armstrong G.T., Kawashima T., Leisenring W., et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the Childhood Cancer Survivor Study. J Clin Oncol. 2014; 32:1218-1227. doi: 10.1200/JCO.2013.51.1055.Berthe M.P. Aleman, Alexandra W. van den Belt-Dusebout et al. Late cardiotoxicity after treatment for Hodgkin Lymphoma. Blood First Edit, 2006, November 21. DOI 10.1182.blood-2006-07034405.Berthe M.P. Aleman, Alexandra W. van den Belt-Dusebout, et al. Late cardiotoxicity after treatment for Hodgkin’s Lymphoma. Blood First Edit, 2006, November 21. DOI 10.1182.blood-2006-07034405.Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869–2879. doi: 10.1002/cncr.11407 23. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672 – 1677. doi:10.1001/jama.1991.03470120074036Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869–2879. doi: 10.1002/cncr.11407Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J, Iliescu C, Ky B, Mayer EL, Okwuosa TM, Plana JC, Ryan TD, Rzeszut AK, Douglas PS. Car- diovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol 2015;65:2739 – 2746. doi: 10.1016/j.jacc.2015.04.059Steinherz L.J., Steinherz P.G., Tan C.T., Heller G., Murphy M.L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266:1672 – 1677. doi:10.1001/jama.1991.03470120074036Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25:38083815. DOI: 10.1200/JCO.2006.10.4976Barac A., Murtagh G., Carver J.R., Chen M.H., Freeman A.M., Herrmann J., Iliescu C., Ky B., Mayer E.L., Okwuosa T.M., Plana J.C., Ryan T.D., Rzeszut A.K., Douglas P.S. Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol 2015;65:2739 – 2746. doi: 10.1016/j.jacc.2015.04.059Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109:3122-3131. DOI: 10.1016/j.jacc.2017.09.1095Pinder M.C., Duan Z., Goodwin J.S., Hortobagyi G.N., Giordano S.H. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007; 25:38083815. DOI: 10.1200/JCO.2006.10.4976Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009, 339: b4606-10.1136. doi: 10.1136/bmj.b4606.Yeh E.T., Tong A.T., Lenihan D.J., et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004; 109:3122-3131. DOI: 10.1016/j.jacc.2017.09.1095de Azambuja E, Ameye L, Diaz M, et al. Cardiac assess- ment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicinbased chemo- therapy. Eur J Cancer 2015;51:2517–2524. doi: 10.1016/j.ejca.2015.08.011Mulrooney D.A., Yeazel M.W., Kawashima T., et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009, 339: b4606-10.1136. doi: 10.1136/bmj.b4606.Paris F, Fuks Z, Kang A, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001;293(5528):2937. DOI: 10.1126/science.1060191de Azambuja E., Ameye L., Diaz M., et al. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicinbased chemotherapy. Eur J Cancer 2015;51:2517–2524. doi: 10.1016/j.ejca.2015.08.011Hatoum OA, Otterson MF, Kopelman D, et al. Radiation induces endothelial dysfunction in murine intestinal arterioles via enhanced production of reactive oxygen species. Arterioscler Thromb Vasc Biol2006;26(2):28794. doi: 10.1161/01.ATV.0000198399.40584.8cParis F., Fuks Z., Kang A., et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001; 293(5528):2937. DOI: 10.1126/science.1060191Weintraub NL, Jones WK, Manka D. Understanding radiationinduced vascular disease. J Am Coll Cardiol 2010;55(12):1237 9. doi: 10.1016/j.jacc.2009.11.053Hatoum O.A, Otterson M.F., Kopelman D., et al. Radiationinduced endothelial dysfunction in murine intestinal arterioles via the enhanced production of reactive oxygen species. Arterioscler Thromb Vasc Biol 2006;26(2):28794. doi: 10.1161/01.ATV.0000198399.40584.8cBasavaraju SR, Easterly CE. Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. Med Phys 2002;29(10):2391 403. doi: 10.1118/1.1509442Weintraub NL, Jones WK, Manka D. Understanding radiationinduced vascular disease. J Am Coll Cardiol 2010;55(12):1237 9. doi: 10.1016/j.jacc.2009.11.053Hayashi T, Morishita Y, Kubo Y, et al. Long-term effects of radiation dose on inflamma- tory markers in atomic bomb survivors. Am J Med 2005;118(1):83 6. doi: 10.1016/j.amjmed.2004.06.045Basavaraju S.R., Easterly C.E. Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. Med Phys 2002; 29(10):2391 403. doi: 10.1118/1.1509442Brosius FC, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med 1981;70(3):519 30.Hayashi T., Morishita Y., Kubo Y., et al. Long-term effects of radiation dose on inflammatory markers in atomic bomb survivors. Am J Med 2005; 118(1):83 6. doi: 10.1016/j.amjmed.2004.06.045Amromin GD, Gildenhorn HL, Solomon RD, Nadkarni BB. The synergism of X-irradiation and cholesterol-fat feeding on the development of coronary artery lesions. J Atheroscler Res 1964;4:325 34. doi: 10.1016/0002-9343(81)90574-xBrosius F.C., Waller B.F., Roberts W.C. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med 1981; 70(3):519 30.Cosyns B., Dulgheru R. The Impact of Radiotherapy. Anticancer Treatments and Cardiotoxicity. 2017. Elsevier Inc. DOI: 10.1016/B978-0-12-802509-3.00005-4Amromin G.D., Gildenhorn H.L., Solomon R.D., Nadkarni B.B. The synergism of X-irradiation and cholesterol-fat feeding on the development of coronary artery lesions. J Atheroscler Res 1964;4:325 34. doi: 10.1016/0002-9343(81)90574-xLancellotti P, Nkomo VT, Badano LP etal. European Society of Cardiology Working Groups on Nuclear Cardiology and Cardiac Computed Tomography and Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, Society of Cardiovascular Computed Tomography. Expert consensus for multimodality imagmg evaluation of cardiovascular complicalions of radiotherapy in adults: a report from the European Associaiion of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2013; 14:721-40. doi: 10.1093/ehjci/jet123.Cosyns B., Dulgheru R. The Impact of Radiotherapy. Anticancer Treatments and Cardiotoxicity. 2017. Elsevier Inc. DOI: 10.1016/B978-0-12-802509-3.00005-4Moazeni et al Anthracycline induced cardiotoxicity: biomarkers and “Omics” technology in the era of patient speci c care. Clin Trans Med (2017) 6:17 DOI 10.1186/s40169-017-0148-3 17Lancellotti P., Nkomo V.T., Badano L.P., et al. European Society of Cardiology Working Groups on Nuclear Cardiology and Cardiac Computed Tomography and Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, Society of Cardiovascular Computed Tomography. Expert consensus for multimodality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2013; 14:721-40. doi: 10.1093/ehjci/jet123.Ledwidge M, Gallagher J, Conlon C et al. Natriuretic peptidebased screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 2013;310:66–74. Doi: 10.1001/jama.2013.7588Moazeni et al Anthracycline-induced cardiotoxicity: biomarkers and “Omics” technology in the era of patient-specific care. Clin Trans Med (2017) 6:17 DOI 10.1186/s40169-017-0148-3 17Amal Zidan et al. NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors. PMC Published online 2015 Apr 16. DOI: 10.1155/2015/513219.Ledwidge M., Gallagher J., Conlon C., et al. Natriuretic peptidebased screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 2013; 310:66–74. Doi: 10.1001/jama.2013.7588Sherief L. M., Kamal A. G., Khalek E. A., Kamal N. M., Soliman A. A. A., Esh A. M. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children. Hematology.2012;17(3):151-156. DOI: 10.1179/102453312Х13376952196412.Amal Zidan, et al. NT-pro-BNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors. PMC Published online 2015 Apr 16. DOI: 10.1155/2015/513219.Mavinkurve-Groothuis A. M. C., Groot-Loonen J., Bellersen L., et al. Abnormal nt-pro-bnp levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines. Pediatric Blood and Cancer. 2009;52(5):631–636. DOI: 10.1002/pbc.21913.Sherief L. M., Kamal A. G., Khalek E. A., Kamal N. M., Soliman A. A. A., Esh A.M. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children. Hematology.2012;17(3):151-156. DOI: 10.1179/102453312Х13376952196412.Juan Carlos Plana et al. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging J Am SocEchocardiogr. 2014;27:91139. Doi: 10.1016/j.echo.2014.07.012Mavinkurve-Groothuis A.M. C., Groot-Loonen J., Bellersen L., et al. Abnormal NT-pro-BNP levels in asymptomatic longterm survivors of childhood cancer treated with anthracyclines. Pediatric Blood and Cancer. 2009;52(5):631–636. DOI: 10.1002/pbc.21913.Cardinale D, Colombo A,Lamantia G. et al. Anthracyclineinduced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am CollCardiol. 2010;55:213–20. doi: 10.1016/j.jacc.2009.03.095Juan Carlos Plana, et al. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging J Am Soc Echocardiography. 2014;27:91139. Doi: 10.1016/j.echo.2014.07.012Ciro Santoro1 et al. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancerpatients: a balance with feasibility. European Heart Journal – Cardiovascular Imaging, Volume 18, Issue 8, 2017, Pages 930–936, doi.org/10.1093/ehjci/jex033Cardinale D., Colombo A., Lamantia G., et al. Anthracyclineinduced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010; 55:213–20. doi: 10.1016/j.jacc.2009.03.095Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civel-li M et al. Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition. Circulation. 2006;114 (23):2474–81. DOI: 10.1161/circulationaha.106.635144Ciro Santoro, et al. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. European Heart Journal – Cardiovascular Imaging, Volume 18, Issue 8, 2017, Pages 930–936, doi.org/10.1093/ehjci/jex033Cadeddu C, Piras A, Mantovani G, et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin induced inflammation, oxidative stress, and early ventricular impairment. American Heart Journal. 2010;160 (3):487.e1–487. e7. DOI: 10.1016/j.ahj.2010.05.037Cardinale D., Colombo A., Sandri M.T., Lamantia G., Colombo N., Civelli M., et al. Prevention of High-Dose ChemotherapyInduced Cardiotoxicity in High-Risk Patients by AngiotensinConverting Enzyme Inhibition. Circulation. 2006; 114 (23):2474–81. DOI: 10.1161/circulationaha.106.635144Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, doubleblind clinical trial of candesartan and metoprolol. European Heart Journal. 2016;37 (21):1671–80. DOI: 10.1093/eurheartj/ehw022Cadeddu C., Piras A., Mantovani G., et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin induced inflammation, oxidative stress, and early ventricular impairment. American Heart Journal. 2010; 160 (3):487.e1–487. e7. DOI: 10.1016/j.ahj.2010.05.037Kalay N, Basar E, Ozdogru I et al. Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy. Journal of the American College of Cardiology. 2006;48 (11):2258–62. DOI: 10.1016/j.jacc. 2006.07.052Gulati G., Heck S.L., Ree A.H., et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, doubleblind clinical trial of candesartan and metoprolol. European Heart Journal. 2016; 37 (21):1671–80. DOI: 10.1093/eurheartj/ehw022Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM et al. Enalapril and Carvedilol for Preventing Chemotherapy-In- duced Left Ventricular Systolic Dysfunction in Patients With Malig- nant Hemopathies. Journal of the American College of Cardiology. 2013;61 (23):2355–62. DOI: 10.1016/j.jacc.2013.02.072Kalay N., Basar E., Ozdogru I., et al. Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy. Journal of the American College of Cardiology. 2006; 48 (11):2258–62. DOI: 10.1016/j.jacc. 2006.07.052Pituskin E, Mackey JR, Koshman S et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101 – Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. Journal of Clinical Oncology. 2017;35 (8):870–7. DOI: 10.1200/JCO.2016.68.7830Bosch X., Rovira M., Sitges M., Domènech A., Ortiz-Pérez J.T., de Caralt T.M., et al. Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies. Journal of the American College of Cardiology. 2013; 61 (23):2355–62. DOI: 10.1016/j.jacc.2013.02.072Maya Guglin, Jeffrey Krischer, Roy Tamura et al Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. JACC .Volume 73, Issue 22, June 2019 DOI: 10.1016/j.jacc.2019.03.495Pituskin E., Mackey J.R., Koshman S., et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101 – Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. Journal of Clinical Oncology. 2017; 35 (8):870–7. DOI: 10.1200/JCO.2016.68.7830Ayalasomayajula S, Langenickel T, Pal P, Boggarapu S, Sunkara G. Cli- nical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. Clinical Pharmacokinetics. 2017;56 (12):1461–78. DOI: 10.1007/s40262-017-0543-3Maya Guglin, Jeffrey Krischer, Roy Tamura, et al Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. JACC. Volume 73, Issue 22, June 2019 DOI: 10.1016/j.jacc.2019.03.495Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT):a randomised placebo-controlled study. The Lancet. 2010;376 (9744):875–85. DOI: 10.1016/S0140–6736(10)61198–1.Ayalasomayajula S., Langenickel T., Pal P., Boggarapu S., Sunkara G. Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. Clinical Pharmacokinetics. 2017; 56 (12):1461–78. DOI: 10.1007/s40262-017-0543-3Васюк Ю. А., Несветов В. В., Школьник Е. Л., Школьник Л. Д., Варлан Г. В., Гендлин Г. Е. и др. Возможности селективного ингибитора ионн ых f-каналов синусового узла ивабрадина в профилактике антрациклиновой кардиотоксичности у больных раком молочной железы. Рациональная Фармакотерапия в Кардиологии. 2017;13 (2):184–90. / Vasyuk Yu. V., Nesvetov V. V., Shkolnik E. L., Shkolnik L. D., Varlan G. V., Gendlin G. E. et al. Possibilities of ivabradine, a selective inhibitor of ionf-channels of sinus node, in prevention of anthracycline cardiotoxicity in patients with breast cancer. Rational Pharmacotherapy in Cardiology. 2017;13 (2):184–90. DOI: 10.20996/1819-6446-2017-13-2-184-190 [in Russian].Swedberg K., Komajda M., Böhm M., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. The Lancet. 2010; 376 (9744):875–85. DOI: 10.1016/S0140–6736(10)61198–1.Robison LL, Armstrong GT, Boice JD, et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol 2009;27:2308–18. doi: 10.1007/s11764-012-0250-xVasyuk Y. Vasyuk Yu.A., Nesvetov V.V., Shkolnik E.L., Shkolnik L.D., Varlan G.V., Gendlin G.E., et al. Possibilities of ivabradine, a selective inhibitor of ion f-channels of the sinus node, in the prevention of anthracycline cardiotoxicity in patients with breast cancer. Rational Pharmacotherapy in Cardiology. 2017; 13 (2):184–90. DOI: 10.20996/1819-6446-2017-13-2-184-190 [in Russian].Leisenring WM, Mertens AC, Armstrong GT, et al. Pediatric cancer survivorship re- search: experience of the Childhood Cancer Survivor Study. J Clin Oncol 2009;27: 2319–27. doi: 10.1007/s11764-014-0354-6Robison L.L., Armstrong G.T., Boice J.D., et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol 2009; 27:2308–18. doi: 10.1007/s11764-012-0250-xLeisenring W.M., Mertens A.C., Armstrong G.T., et al. Pediatric cancer survivorship research: experience of the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27: 2319–27. doi: 10.1007/s11764-014-0354-6Leisenring W.M., Mertens A.C., Armstrong G.T., et al. Pediatric cancer survivorship research: experience of the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27: 2319–27. doi: 10.1007/s11764-014-0354-6

The authors declare that there are no conflicts of interest present.